celltrion

South Korea’s leading biosimilar drug developer Celltrion Inc. on Sunday unveiled an anticancer medicine to expand new pipelines and accelerat...

South Korea’s biopharmaceutical giant Celltrion Inc. has solidified its presence in South America after winning supply contracts for its flags...

Celltrion Inc. said Wednesday it has received regulatory approval from Australia’s Therapeutic Goods Administration (TGA) for three biosimilar...

South Korea’s leading biosimilar drug developer Celltrion Inc. said on Monday it is set to sell Steqeyma, a biosimilar to autoimmune disease t...

South Korea’s leading biosimilar drug developer Celltrion Inc. announced on Friday a plan to cancel $140 million worth of treasury shares to i...

Samsung Bioepis Co. and Celltrion Inc. are outpacing long-established global drug manufacturers such as Amgen Inc. and Sandoz in the antibody biosim...

Celltrion Inc.’s Avtozma, a biosimilar to Roche’s autoimmune disease treatment Actemra, has won approval from the European Commission, f...

South Korea’s leading biosimilar drug developer Celltrion Inc.'s Vegzelma, a cancer drug referencing global biopharma Roche’s Avastin, h...

SAN FRANCISCO – South Korea’s leading biosimilar drug developer Celltrion Inc. seeks to acquire a domestic health food maker as early as...

South Korea’s two leading drugmakers, Celltrion Inc. and Samsung Bioepis Co., have achieved a significant milestone in the European biosimilar...

South Korea's Celltrion Inc. said on Wednesday it received new drug submission (NDS) approval from the Food and Drug Administration (FDA) for Steq...

Celltrion Inc. on Tuesday launched its contract development and manufacturing organization unit Celltrion BioSolutions Co. in its foray into the CDM...

Celltrion Inc. is one step closer to commercializing its four new biosimilars in Europe after a committee of the European Medicines Agency (EMA) rec...

South Korea’s biosimilar maker Celltrion Inc. on Friday announced a plan to allot cash and stock dividends simultaneously. The company wi...

South Korea’s Celltrion Inc., received new drug submission (NDS) approval from Health Canada for Omlyclo, the biosimilar of allergic asthma an...

South Korea’s biosimilar maker Celltrion Inc. on Wednesday announced a plan to retire about a quarter of its treasury stock worth 563 billion ...

South Korea’s leading biosimilar developer Celltrion Inc. will break ground on its first contract development and manufacturing organization (...

Celltrion Inc.'s Remsima, the world’s first biosimilar monoclonal antibody, is on track to exceed 1 trillion won ($713 million) in sales this ...

South Korea's Celltrion Inc. announced on Thursday that it decided to repurchase additional treasury shares worth 100 billion won ($71.6 million).Fr...

South Korea's Celltrion Inc. said on Friday that it completed its acquisition of iQone Healthcare Switzerland, a Swiss pharmaceutical distributor, t...

MSCI announced on Wednesday that South Korea's Hyundai Rotem Co. will be added to the Morgan Stanley Capital International (MSCI) Korea Index. ...

South Korea's Celltrion Inc. said on Monday it released Steqeyma (ustekinumab) in Europe, the biosimilar of autoimmune disease treatment Stelara.T...

South Korean biosimilar maker Celltrion Inc. said on Monday its subcutaneous injection formulation for autoimmune diseases, Zymfentra (infliximab), ...

Celltrion Inc., South Korea’s largest biosimilar maker, said on Friday it plans to establish a contract development and manufacturing organiza...

South Korea’s Celltrion Inc. said on Friday that its cancer treatments have captured a 90% market share in several Central American countries....

Celltrion Inc., South Korea’s largest biosimilar maker, said on Monday that it completed the establishment of a local subsidiary in Vietnam....

Celltrion Inc., South Korea’s largest biosimilar maker, announced on Friday that its breast and stomach cancer treatment "Herzuma" (active ing...

Celltrion Inc., South Korea’s largest biosimilar maker, will spend several billion dollars to build a factory to crack the contract developmen...

South Korea’s biosimilar maker Celltrion Inc. will venture into the contract development and manufacturing organization (CDMO) market, the com...

South Korea’s largest biosimilar maker Celltrion Inc. said on Friday that it has scrapped a plan to merge with Celltrion Pharm Inc., an R&...